{"entity":{"id":"cd86","kind":"target","name":"CD86 (B7-2)","aka":["B7-2","B7.2","CD28LG2","CD86 molecule"],"tldr":"CD86 is one of the two B7 molecules on antigen-presenting cells that either wake a T cell up (through CD28) or calm it down (through CTLA-4). Ipilimumab works by stopping CTLA-4 from hogging CD86 and CD80.","summary":"CD86 (chromosome 3q13.33) is a costimulatory molecule of the immunoglobulin superfamily on the surface of antigen-presenting cells that acts as the primary auxiliary signal augmenting the MHC/TCR signal in naive T cells by binding the constitutively expressed CD28 receptor (UniProt P42081). CTLA-4 binds CD80 and CD86 with considerably stronger affinity than CD28 does and acts as a decoy receptor (UniProt P16410), which is the interaction anti-CTLA-4 antibodies release.","asOf":"2026-09-24","links":[{"label":"HGNC HGNC:1705","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1705"},{"label":"UniProt P42081","url":"https://www.uniprot.org/uniprotkb/P42081/entry"},{"label":"NCBI Gene 942","url":"https://www.ncbi.nlm.nih.gov/gene/942"}],"tags":["checkpoint-map"],"related":["cd80","ctla4","cd28","ipilimumab"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":["pd1-checkpoint","cancer-immunity-cycle"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Prevalence not recorded: HGNC and UniProt carry no positivity rates."],"provenance":{"editedBy":"OnCo checkpoint map (HGNC REST, UniProt REST, ClinicalTrials.gov v2)","editedOn":"2026-09-24"},"symbol":"CD86","role":["immune-checkpoint"],"sources":[{"label":"HGNC HGNC:1705","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1705","note":"approved symbol, name, aliases and cross-references"},{"label":"UniProt P42081","url":"https://www.uniprot.org/uniprotkb/P42081/entry","note":"protein name, function and tissue specificity"}],"specificitySources":[],"hgnc":"HGNC:1705","ensembl":"ENSG00000114013","uniprot":"P42081","entrez":"942","biology":"Shares the CD28/CTLA-4 ligand role with CD80; no drug in the corpus binds CD86 directly.","whereFound":["Antigen-presenting cells (UniProt P42081)"],"targetClass":"checkpoint","prevalence":[]},"route":"/targets/cd86/","neighbours":{"target":[{"id":"cd28","kind":"target","name":"CD28","route":"/targets/cd28/"},{"id":"cd80","kind":"target","name":"CD80 (B7-1)","route":"/targets/cd80/"},{"id":"ctla4","kind":"target","name":"CTLA-4","route":"/targets/ctla4/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"}],"pathway":[{"id":"pd1-checkpoint","kind":"pathway","name":"PD-1 / PD-L1 immune checkpoint & T-cell activation","route":"/pathways/pd1-checkpoint/"},{"id":"cancer-immunity-cycle","kind":"pathway","name":"The cancer-immunity cycle","route":"/pathways/cancer-immunity-cycle/"}],"term":[{"id":"checkpoint","kind":"term","name":"Checkpoint (two meanings)","route":"/terms/checkpoint/"}]}}